PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
1-Year Est. Return
13.3%
1 Year Est. Return
+13.3%
AUM
$2.17B
AUM Growth
-$702M
(-24%)
Holding
33
Top Buys
| 1 | +$70.7M | |
| 2 | +$34.5M | |
| 3 | +$34.4M | |
| 4 |
MTSR
Metsera Inc
MTSR
|
+$32.4M |
| 5 |
Cogent Biosciences
COGT
|
+$24.2M |
Top Sells
| 1 | +$250M | |
| 2 | +$60.8M | |
| 3 | +$44.7M | |
| 4 |
Pliant Therapeutics
PLRX
|
+$42.1M |
| 5 |
TECX
Tectonic Therapeutic
TECX
|
+$22.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$6.67B
| $374M | 17.12% |
5,269,433
-93,946
|
|
||
2
Arcellx
ACLX
$4.82B
| $295M | 13.5% |
4,492,032
+120,431
|
|
||
3
Revolution Medicines
RVMD
$10.1B
| $218M | 10.01% |
6,178,111
-375,000
|
|
||
|
ONC
4
BeOne Medicines Ltd
ONC
$34.8B
| $181M | 8.3% |
666,024
+50,000
|
|
||
5
Merus
MRUS
$7.19B
| $142M | 6.5% |
3,369,699
+1,679,777
|
|
||
6
Tarsus Pharmaceuticals
TARS
$3.08B
| $134M | 6.14% |
2,610,197
+78,301
|
|
||
7
Edgewise Therapeutics
EWTX
$1.59B
| $96.7M | 4.43% |
4,394,556
-99,373
|
|
||
8
Janux Therapeutics
JANX
$1.61B
| $89.9M | 4.12% |
3,329,909
-186,077
|
|
||
9
Crinetics Pharmaceuticals
CRNX
$3.91B
| $65.3M | 2.99% |
1,946,168
+35,407
|
|
||
10
Vaxcyte
PCVX
$5.5B
| $64.1M | 2.93% |
1,696,481
+273,694
|
|
||
11
Disc Medicine
IRON
$3.13B
| $60.1M | 2.75% |
1,210,971
-286,749
|
|
||
|
12
Cogent Biosciences
COGT
$2.29B
| $53.7M | 2.46% |
8,963,655
+4,046,243
|
|
||
|
LENZ
13
LENZ Therapeutics
LENZ
$1.16B
| $38.9M | 1.78% |
1,511,932
+741,477
|
|
||
14
Apogee Therapeutics
APGE
$3.73B
| $35.9M | 1.65% |
961,707
-322,059
|
|
||
15
argenx
ARGX
$51.9B
| $35.3M | 1.62% |
59,679
-421,626
|
|
||
16
Cytokinetics
CYTK
$6.99B
| $34.5M | 1.58% |
+858,664
|
|
||
17
Insmed
INSM
$35B
| $34.4M | 1.58% |
+451,359
|
|
||
18
Spyre Therapeutics
SYRE
$1.74B
| $34.3M | 1.57% |
2,127,205
+600,000
|
|
||
|
MTSR
19
Metsera Inc
MTSR
$5.58B
| $32.4M | 1.49% |
+1,191,462
|
|
||
20
Viridian Therapeutics
VRDN
$1.98B
| $28.2M | 1.29% |
2,095,079
+275,000
|
|
||
21
Olema Pharmaceuticals
OLMA
$642M
| $25.3M | 1.16% |
6,741,172
-563,798
|
|
||
22
MoonLake Immunotherapeutics
MLTX
$579M
| $24.5M | 1.12% |
627,423
-1,144,788
|
|
||
23
Arcutis Biotherapeutics
ARQT
$2.5B
| $22.9M | 1.05% |
+1,465,334
|
|
||
|
YMAB
24
DELISTED
Y-mAbs Therapeutics
YMAB
| $18.8M | 0.86% |
4,236,346
|
|
||
25
Erasca
ERAS
$686M
| $14.8M | 0.68% |
10,802,354
+50,000
|
|